Researchers at the Fred Hutchinson Cancer Research Center found that autoantibodies targeting the exoproteome reshaped checkpoint inhibitor responses and opened new avenues to enhance immunotherapy. In the study published in the July 23, 2025, issue of Nature, the authors set out to address a long-standing question in cancer immunotherapy: why patients with the same type of cancer, treated with the same immunotherapy, can experience such drastically different outcomes. Read More
Thoracic aortic dissection can progress to a highly lethal cardiac emergency, but it cannot usually be detected in early stages, so suitable biomarkers of progression are needed. Levels of C-reactive protein in serum rise during progression, but they also rise in infectious or autoimmune conditions, making the biomarker nonspecific. Read More
The U.S. FDA has cleared Zymeworks Inc.’s IND application for ZW-251, a novel glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) incorporating the company’s proprietary topoisomerase 1 (TOPO1) inhibitor payload, ZD-06519, for the treatment of hepatocellular carcinoma (HCC). Read More
Researchers from Biotiche Drug Discovery Srl and collaborators have discovered that modulating the activity of a specific family of potassium channels, known as Kv3 channels, can have beneficial effects on the progression of amyotrophic lateral sclerosis (ALS) in a mouse model of the disease. The study, published in the journal Acta Neuropathologica Communications, provides new insights into the role of these channels in skeletal muscle function and their potential as a therapeutic target for ALS. Read More
Activating apoptosis of tumor cells by binding a soluble form of the membrane protein TRAIL to its surface receptors DR4 and DR5 on the tumor surface shows promise as a cancer therapy, but the ligand on its own has only a minutes-long half-life and does not strongly activate the receptors. Read More
The chaperone protein Hsp90 is overexpressed in many cancers, where it helps protect and drive cell proliferation by stabilizing growth factor receptors and promoting their downstream signaling. Hsp90 inhibitors show anticancer potential, but many induce substantial adverse effects. Read More
Work at Libra Therapeutics Inc. has led to the identification of new mucolipin-1 (MCOLN1; TRPML1) activators reported to be useful for the treatment of metabolic diseases, infections, hematologic diseases, inflammation, cardiovascular, eye, neurological and renal disorders, among others. Read More
Pelemed Co. Ltd. has prepared pyrrolotriazine derivatives acting as tyrosine-protein kinase Yes (YES1) inhibitors reported to be useful for the treatment of cancer. Read More
The sialyltransferase ST6GAL1 is upregulated in several types of cancer and its expression is particularly elevated in triple-negative breast cancer, which is extremely aggressive and associated with very poor prognosis. Read More
Serine/threonine-protein kinase WNK1 inhibitors have been described in a Dania Therapeutics ApS patent as potentially useful for the treatment of cancer and hypertension. Read More
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have discovered new heteroarylphenyl ether derivatives acting as cyclin-dependent kinase CDK8/cyclin C inhibitors. As such, they are reported to be useful for the treatment of graft-vs.-host disease, transplant rejection, multiple sclerosis, rheumatoid arthritis, atopic dermatitis, psoriasis, amyotrophic lateral sclerosis and stroke, among others. Read More
The autoimmune disorder systemic lupus erythematosus (SLE) involves upregulation of IgD, and studies have shown that anti-IgD antibodies can alleviate the autoimmune disorder rheumatoid arthritis in mouse models. Building on this finding, researchers in Hefei and Changshu, China, have shown that interrupting the interaction between IgD and its receptor FcδR can reduce cytokine levels and phosphorylation of JAK2 and STAT3, suppressing the activation and proliferation of CD4+ T cells in SLE. Read More
